0001564590-19-006490.txt : 20190306 0001564590-19-006490.hdr.sgml : 20190306 20190306161919 ACCESSION NUMBER: 0001564590-19-006490 CONFORMED SUBMISSION TYPE: S-8 PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20190306 DATE AS OF CHANGE: 20190306 EFFECTIVENESS DATE: 20190306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001178711 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330960223 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-230097 FILM NUMBER: 19662756 BUSINESS ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: (617) 807-6600 MAIL ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc DATE OF NAME CHANGE: 20090130 FORMER COMPANY: FORMER CONFORMED NAME: NOVACEA INC DATE OF NAME CHANGE: 20020724 S-8 1 prtk-s8.htm S-8 prtk-s8.DOCX.htm

 

 

Registration No. 333-

As filed with the Securities and Exchange Commission on March 6, 2019

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE

SECURITIES ACT OF 1933

 

 

PARATEK PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

33-0960223

(State or other jurisdiction of
incorporation or organization)

 

(IRS Employer
Identification No.)

 

 

75 Park Plaza

Boston, MA 02116

(Address of Principal Executive Offices) (Zip Code)

 

 

Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan

(Full titles of the plans)

 

 

Michael F. Bigham
Chairman and Chief Executive Officer
75 Park Plaza

Boston, MA 02116

(Name and address of agent for service)

 

(617) 807-6600

(Telephone number, including area code, of agent for service)

 

 

Please send copies of all communications to:

 

 

 

 

 

 

 

William M. Haskel

Senior Vice President, General Counsel and Corporate Secretary

Paratek Pharmaceuticals, Inc.

75 Park Plaza

Boston, MA 02116

(617) 807-6600

 

Christopher D. Comeau

Ropes & Gray LLP

Prudential Tower

800 Boylston Street

Boston, MA 02199

(617) 951-7000

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 

 

 


 

 

 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

 

 

 

 

Title of Each Class of
Securities to be Registered

 

Amount to be
Registered (1)

 

Proposed Maximum
Offering Price Per
Share

 

Proposed Maximum
Aggregate Offering Price

 

Amount of
Registration
Fee

 

Common Stock, $0.001 par value per share

 

1,612,969 shares (2)

 

 

$6.50 (3)

 

 

$10,484,298.50

 

 

$1,270.70

 

TOTAL

 

1,612,969 shares

 

 

 

 

$10,484,298.50

 

 

$1,270.70

 

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, this Registration Statement also covers such additional shares of Common Stock as may issued to prevent dilution from stock splits, stock dividends and similar transactions.

(2)

Represents 1,612,969 shares of Common Stock that were automatically added to the shares authorized for issuance under the registrant’s 2015 Equity Incentive Plan (the “2015 Plan”) on January 1, 2019 pursuant to an “evergreen” provision contained in the 2015 Plan. The “evergreen” provision provides that on each January 1st from January 1, 2015 through January 1, 2025, the number of shares of Common Stock available for issuance under the 2015 Plan will automatically increase annually in an amount equal to the lesser of 5% of outstanding shares of the registrant’s Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the registrant’s board of directors.

(3)

Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) of the Securities Act of 1933 based on the average of high and low prices of the registrant’s Common Stock as reported by The Nasdaq Global Market on March 1, 2019, a date that is within five business days prior to the date on which this Registration Statement is being filed, to be $6.65 and $6.35, respectively.

 

 

 

 

 

 

 

 


 


 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed to register an additional 1,612,969 shares under the Registrants 2015 Equity Incentive Plan. Pursuant to Instruction E to Form S-8, the Registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth herein, into this Registration Statement the entire contents of its Registration Statement on Form S-8 (File No. 333-205482) filed with the Securities and Exchange Commission (the SEC) on July 2, 2015, its Registration Statement on Form S-8 (File No. 333-210053) filed with the SEC on March 9, 2016, its Registration Statement on Form S-8 (File No. 333-217660) filed with the SEC on May 4, 2017 and its Registration Statement on Form S-8 (File No. 333-224781) filed with the SEC on May 9, 2018.

.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8. Exhibits.

 

 

 

 

 

Incorporated by Reference

Exhibit
Number

 

 

Description

 

Schedule / Form

 

File Number

 

Exhibit

 

Filing Date

 

4.1

 

 

Amended and Restated Certificate of Incorporation of Paratek Pharmaceuticals, Inc.

 

Form 8-K

 

001-36066

 

3.1

 

October 31, 2014

 

 

 

 

 

 

 

4.2

 

 

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Paratek Pharmaceuticals, Inc.

 

Form 8-K

 

001-36066

 

3.2

 

October 31, 2014

 

 

 

 

 

 

 

4.3

 

 

Certificate of Elimination of Series A Junior Participating Preferred Stock.

 

Form 8-K

 

001-36066

 

3.1

 

July 24, 2015

 

 

 

 

 

 

 

4.4

 

 

Amended and Restated Bylaws.

 

Form 8-K

 

001-36066

 

3.1

 

April 16, 2015

 

 

 

 

 

 

 

4.5

 

 

Specimen Common Stock Certificate.

 

Form S-3

 

333-201458

 

4.2

 

January 12, 2015

 

 

 

 

 

 

 

4.6

 

 

2015 Equity Incentive Plan.

 

Form S-8

 

333-205482

 

99.5

 

July 2, 2015

 

 

 

 

 

 

 

4.7

 

 

Form of Stock Option Grant Notice and Option Agreement under the 2015 Equity Incentive Plan.

 

Form S-8

 

333-205482

 

99.6

 

July 2, 2015

 

 

 

 

 

 

 

4.8

 

 

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2015 Equity Incentive Plan.

 

Form S-8

 

333-205482

 

99.7

 

July 2, 2015

 

 

 

 

 

 

 

4.9

 

 

Form of Leadership Team Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2015 Equity Incentive Plan.

 

Form 8-K

 

001-36066

 

10.1

 

August 4, 2017

 

 

 

 

 

 

 

4.10

 

 

Form of Director Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2015 Equity Incentive Plan.

 

Form 10-K

 

001-36066

 

10.6E

 

March 6, 2018

 

 

 

 

 

 

 

4.11

 

 

Form of Director Stock Option Grant Notice and Option Agreement under the 2015 Equity Incentive Plan.

 

Form 10-K

 

001-36066

 

10.6F

 

March 6, 2018

 

 

 

 

 

 

 

5.1*

 

 

Opinion of Ropes & Gray LLP

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23.1*

 

 

Consent of Ernst & Young LLP, an independent registered public accounting firm

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23.3*

 

 

Consent of Ropes & Gray LLP (contained in Exhibit 5.1 to this Registration Statement)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24.1

 

 

Power of Attorney (included on the signature page of this Registration Statement)

 

 

 

 

 

 

 

 

________________

 

*

Filed herewith.

 


 


 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 6th day of March, 2019.

 

 

PARATEK PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ Michael. F. Bigham

 

 

Name: Michael F. Bigham

 

 

Title: Chairman and Chief Executive Officer

 

POWER OF ATTORNEY

 

Each person whose signature appears below constitutes and appoints Douglas W. Pagán and William M. Haskel, and each of them acting individually, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Paratek Pharmaceuticals, Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

* * * *

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Michael. F. Bigham

 

Chairman and Chief Executive Officer

 

March 6, 2019

Michael F. Bigham

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Douglas W. Pagán

 

Chief Financial Officer

 

March 6, 2019

Douglas W. Pagán

 

(Principal Financial and Accounting Officer)

 

 

  

/s/ Evan Loh, M.D.

Evan Loh, M.D.

 

 

 President, Chief Operating Officer,

Chief Medical Officer and Director

 

 

 

 March 6, 2019

/s/ Thomas J. Dietz, Ph.D.

 

Director

 

March 6, 2019

Thomas J. Dietz, Ph. D.

 

 

 

 

 

 

 

 

 

/s/ Timothy R. Franson, M.D.

 

Director

 

March 6, 2019

Timothy R. Franson, M.D.

 

 

 

 

 

/s/ Rolf K. Hoffmann

 

Director

 

March 6, 2019

Rolf K. Hoffmann

 

 

 

 

 

 

 

 

 

/s/ Kristine Peterson

 

Director

 

March 6, 2019

Kristine Peterson

 

 

 

 

 

 

 

 

 

/s/ Robert S. Radie

 

Director

 

March 6, 2019

Robert S. Radie

 

 

 

 

 

 

 

 

 

/s/ Jeffrey Stein, Ph.D.

 

Director

 

March 6, 2019

Jeffrey Stein, Ph.D.

 

 

 

 

  

 

EX-5.1 2 prtk-ex51_17.htm EX-5.1 prtk-ex51_17.htm

 

 

Exhibit 5.1

 

ROPES & GRAY LLP

PRUDENTIAL TOWER

800 BOYLSTON STREET

BOSTON, MA 02199-3600

WWW.ROPESGRAY.COM

 

March 6, 2019

 

Paratek Pharmaceuticals, Inc.
75 Park Plaza

Boston, MA 02116

 

Re:

Registration Statement on Form S-8

 

Ladies and Gentlemen:

 

This opinion is furnished to you in connection with the registration statement on Form S-8 (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), for the registration of an aggregate of 1,612,969 shares of common stock, $0.001 par value (the “Shares”), of Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issuable under the Company’s 2015 Equity Incentive Plan (the “Plan”).

 

We are familiar with the actions taken by the Company in connection with the adoption of the Plan. For purposes of our opinion, we have examined and relied upon such documents, records, certificates and other instruments as we have deemed necessary.

 

The opinions expressed below are limited to the Delaware General Corporation Law.

 

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the Plan, the Shares will be validly issued, fully paid and nonassessable.

 

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement.  In giving this consent we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.


 

Very truly yours,

 

/s/ Ropes & Gray LLP

 

Ropes & Gray LLP

 

 

 

EX-23.1 3 prtk-ex231_55.htm EX-23.1 prtk-ex231_55.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan of our reports dated March 5, 2019, with respect to the consolidated financial statements of Paratek Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Paratek Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2018, filed with the Securities and Exchange Commission.

 

/s/ Ernst & Young LLP

 

Boston, Massachusetts

March 6, 2019

 

GRAPHIC 4 glr3meuxpxr2000001.jpg GRAPHIC begin 644 glr3meuxpxr2000001.jpg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